Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
Identifieur interne : 000536 ( 2020/Analysis ); précédent : 000535; suivant : 000537Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
Auteurs : M. Bizzarri [Italie] ; A S Laganà ; D. Aragona ; V. UnferSource :
- European review for medical and pharmacological sciences [ 2284-0729 ] ; 2020.
Descripteurs français
- KwdFr :
- Humains, Infections à coronavirus (), Infections à coronavirus (physiopathologie), Infections à coronavirus (traitement médicamenteux), Inositol (usage thérapeutique), Interleukine-6 (métabolisme), Pandémies, Pneumopathie virale (), Pneumopathie virale (physiopathologie), Pneumopathie virale (traitement médicamenteux), Régulation négative, Tumeurs du poumon (métabolisme).
- MESH :
- métabolisme : Interleukine-6, Tumeurs du poumon.
- physiopathologie : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Inositol.
- Humains, Infections à coronavirus, Pandémies, Pneumopathie virale, Régulation négative.
English descriptors
- KwdEn :
- Betacoronavirus (drug effects), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (physiopathology), Cytokine Release Syndrome (etiology), Down-Regulation, Humans, Inositol (therapeutic use), Interleukin-6 (metabolism), Lung Neoplasms (metabolism), Pandemics, Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (physiopathology).
- MESH :
- chemical , metabolism : Interleukin-6.
- chemical , therapeutic use : Inositol.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- etiology : Cytokine Release Syndrome.
- metabolism : Lung Neoplasms.
- physiopathology : Coronavirus Infections, Pneumonia, Viral.
- Down-Regulation, Humans, Pandemics.
Abstract
The outbreak of Sars-CoV-2 (COVID-19) poses serious challenges to people's health worldwide. The management of the disease is mostly supportive, and respiratory failure from acute respiratory distress syndrome is the leading cause of death in a significant proportion of affected patients. Preliminary data point out that dramatic increase in IL-6 and subsequent cytokine release syndrome may account for the development of fatal interstitial pneumonia. Inhibition of IL-6 by blocking its specific receptor with monoclonal antibodies has been advocated as a promising attempt. Here we assess the potential utility of myo-Inositol, a polyol already in use for treating the newborn Respiratory Distress Syndrome, in downregulating the inflammatory response upon Sars-CoV-2 infection. Myo-Inositol proved to reduce IL-6 levels in a number of conditions and to mitigate the inflammatory cascade, while being devoid of any significant side effects. It is tempting to speculate that inositol could be beneficial in managing the most dreadful effects of Sars-CoV-2 infection.
DOI: 10.26355/eurrev_202003_20715
PubMed: 32271462
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000263
- to stream PubMed, to step Curation: 000263
- to stream PubMed, to step Checkpoint: 000426
- to stream Ncbi, to step Merge: 003846
- to stream Ncbi, to step Curation: 003846
- to stream Ncbi, to step Checkpoint: 003846
- to stream Main, to step Merge: 000536
- to stream Main, to step Curation: 000536
- to stream Main, to step Exploration: 000536
- to stream 2020, to step Extraction: 000536
Links to Exploration step
pubmed:32271462Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?</title><author><name sortKey="Bizzarri, M" sort="Bizzarri, M" uniqKey="Bizzarri M" first="M" last="Bizzarri">M. Bizzarri</name><affiliation wicri:level="3"><nlm:affiliation>Department of Experimental Medicine, Sapienza University, Rome, Italy. mariano.bizzarri@uniroma1.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Experimental Medicine, Sapienza University, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Lagana, A S" sort="Lagana, A S" uniqKey="Lagana A" first="A S" last="Laganà">A S Laganà</name></author><author><name sortKey="Aragona, D" sort="Aragona, D" uniqKey="Aragona D" first="D" last="Aragona">D. Aragona</name></author><author><name sortKey="Unfer, V" sort="Unfer, V" uniqKey="Unfer V" first="V" last="Unfer">V. Unfer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32271462</idno><idno type="pmid">32271462</idno><idno type="doi">10.26355/eurrev_202003_20715</idno><idno type="wicri:Area/PubMed/Corpus">000263</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000263</idno><idno type="wicri:Area/PubMed/Curation">000263</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000263</idno><idno type="wicri:Area/PubMed/Checkpoint">000426</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000426</idno><idno type="wicri:Area/Ncbi/Merge">003846</idno><idno type="wicri:Area/Ncbi/Curation">003846</idno><idno type="wicri:Area/Ncbi/Checkpoint">003846</idno><idno type="wicri:Area/Main/Merge">000536</idno><idno type="wicri:Area/Main/Curation">000536</idno><idno type="wicri:Area/Main/Exploration">000536</idno><idno type="wicri:Area/2020/Extraction">000536</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?</title><author><name sortKey="Bizzarri, M" sort="Bizzarri, M" uniqKey="Bizzarri M" first="M" last="Bizzarri">M. Bizzarri</name><affiliation wicri:level="3"><nlm:affiliation>Department of Experimental Medicine, Sapienza University, Rome, Italy. mariano.bizzarri@uniroma1.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Experimental Medicine, Sapienza University, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Lagana, A S" sort="Lagana, A S" uniqKey="Lagana A" first="A S" last="Laganà">A S Laganà</name></author><author><name sortKey="Aragona, D" sort="Aragona, D" uniqKey="Aragona D" first="D" last="Aragona">D. Aragona</name></author><author><name sortKey="Unfer, V" sort="Unfer, V" uniqKey="Unfer V" first="V" last="Unfer">V. Unfer</name></author></analytic><series><title level="j">European review for medical and pharmacological sciences</title><idno type="eISSN">2284-0729</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (drug effects)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (physiopathology)</term><term>Cytokine Release Syndrome (etiology)</term><term>Down-Regulation</term><term>Humans</term><term>Inositol (therapeutic use)</term><term>Interleukin-6 (metabolism)</term><term>Lung Neoplasms (metabolism)</term><term>Pandemics</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (physiopathology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Humains</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (physiopathologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Inositol (usage thérapeutique)</term><term>Interleukine-6 (métabolisme)</term><term>Pandémies</term><term>Pneumopathie virale ()</term><term>Pneumopathie virale (physiopathologie)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Régulation négative</term><term>Tumeurs du poumon (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interleukin-6</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Inositol</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cytokine Release Syndrome</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Interleukine-6</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inositol</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Down-Regulation</term><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Infections à coronavirus</term><term>Pandémies</term><term>Pneumopathie virale</term><term>Régulation négative</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The outbreak of Sars-CoV-2 (COVID-19) poses serious challenges to people's health worldwide. The management of the disease is mostly supportive, and respiratory failure from acute respiratory distress syndrome is the leading cause of death in a significant proportion of affected patients. Preliminary data point out that dramatic increase in IL-6 and subsequent cytokine release syndrome may account for the development of fatal interstitial pneumonia. Inhibition of IL-6 by blocking its specific receptor with monoclonal antibodies has been advocated as a promising attempt. Here we assess the potential utility of myo-Inositol, a polyol already in use for treating the newborn Respiratory Distress Syndrome, in downregulating the inflammatory response upon Sars-CoV-2 infection. Myo-Inositol proved to reduce IL-6 levels in a number of conditions and to mitigate the inflammatory cascade, while being devoid of any significant side effects. It is tempting to speculate that inositol could be beneficial in managing the most dreadful effects of Sars-CoV-2 infection.</div></front></TEI><affiliations><list><country><li>Italie</li></country><region><li>Latium</li></region><settlement><li>Rome</li></settlement></list><tree><noCountry><name sortKey="Aragona, D" sort="Aragona, D" uniqKey="Aragona D" first="D" last="Aragona">D. Aragona</name><name sortKey="Lagana, A S" sort="Lagana, A S" uniqKey="Lagana A" first="A S" last="Laganà">A S Laganà</name><name sortKey="Unfer, V" sort="Unfer, V" uniqKey="Unfer V" first="V" last="Unfer">V. Unfer</name></noCountry><country name="Italie"><region name="Latium"><name sortKey="Bizzarri, M" sort="Bizzarri, M" uniqKey="Bizzarri M" first="M" last="Bizzarri">M. Bizzarri</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000536 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000536 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= 2020
|étape= Analysis
|type= RBID
|clé= pubmed:32271462
|texte= Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i -Sk "pubmed:32271462" \
| HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |